Skip to main content

Table 3 Antimicrobial susceptibilities of the 61 CPE isolates (2011–2016, Reunion Island, France). a Two isolates harboured two carbapenemase-encoding genes: one K. pneumoniae isolate harboured blaNDM-1 and blaOXA-181, and one E. coli isolate harboured blaNDM-1 and blaVIM-2. b The clinical breakpoints for imipenem (0.125–4) were used to determine the susceptibility of the isolate of P. mirabilis. c Because of the intrinsic resistance of the P. mirabilis species to tigecycline, one isolate of P. mirabilis harbouring blaNDM-1 was excluded for the calculation of non-susceptibility rate of tigecycline. The PK/PD clinical breakpoints for tigecycline (EUCAST 2019; 0.5–0.5) were used to determine the susceptibility of other isolates than E. coli. d Because of the intrinsic resistance of the S. marcescens and P. mirabilis species to colistin, one isolate of P.mirabilis harbouring blaNDM-1 and 3 isolates of S.marcescens harbored blaIMP-10 were excluded for the calculation of non-susceptibility rate of colistin (N.D.: not determined)

From: Carbapenemase-producing Enterobacteriaceae circulating in the Reunion Island, a French territory in the Southwest Indian Ocean

AntimicrobialsCarbapenemase-encoding genes
(% of non-susceptible isolates)
MIC Range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
blaNDMablaIMIblaIMP-10blaOXA-181TotalMin.Max.  
(n = 50)(n = 7)(n = 3)(n = 1)(n = 61)  
Ertapenem9671.4100091.80.2532832
Imipenem66b100100070.5b0.532632
Meropenem8414.3100075.4132632
Tigecycline34.7c14.3100033.3c0.032240.386
Colistin6.1d100NDd017.5d0.06640.2532
Fosfomycin2201000230.125102412128